Unwanted immunogenicity testing – Challenges linger despite guidance and improved requirements
Feature ArticlesRalf D. Hess, PhD • Sven J. Hoffmann, MSc • Jennifer Neff, PhD, MBA, RAC, RCC • Dominik M. Aumer, MBA • Moritz Haucke, MBA • Simon D. Schulz, PhD
EuropeGlobalPharmaceuticalsPharmacovigilanceUnited States